US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
List view / Grid view
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
As a technology, mass spectrometry (MS) has evolved to the point where it is used throughout the drug development process. In particular, when MS is coupled with high-performance liquid chromatography (HPLC) it adds an orthogonal detection function for sample analysis and provides unique capabilities for pharmaceutical analysis, such as sensitivity,…
11 July 2016 | By Victoria White, Digital Content Producer
The FDA has approved Genentech’s Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age...
In this Mass Spectrometry In-Depth Focus: Novel trends in glycosylation analysis of biotherapeutics by mass spectrometry; The use of mass spectrometry for the characterisation of proteins in small molecule drug discovery; Mass Spectrometry Q&A...
22 March 2016 | By Victoria White
The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer...
1 March 2016 | By Victoria White
The FDA has approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma...
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
15 May 2013 | By Astellas Pharma Inc.
The FDA also approved the cobas® EGFR Mutation Test, which was developed by Roche and validated in the pivotal EURTAC study...
8 August 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. has signed a definitive agreement...